Axsome Therapeutics (AXSM) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Axsome Therapeutics (AXSM) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 43.3% versus a loss of 12.8%. Over five years, AXSM leads with a +324.1% price change compared with -7.6% for RDY. Dr. Reddy's Laboratories is the larger company by market cap ($10.16 billion vs $8.91 billion), about 1.1 times the size, while Axsome Therapeutics is growing revenue faster (+65.5% vs +13.8%).
On valuation, Dr. Reddy's Laboratories trades at a lower forward P/E (19.0x vs 36.2x for Axsome Therapeutics). Dr. Reddy's Laboratories pays a dividend yielding 65.57%, while Axsome Therapeutics does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus -28.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | RDY |
|---|---|---|
| Share price | $170.08 | $12.20 |
| Market cap | $8.91B | $10.16B |
| 1-day change | -1.67% | -0.57% |
| YTD return | -6.88% | -13.11% |
| 1-year return | +43.27% | -12.79% |
| 5-year return | +324.14% | -7.59% |
| P/E ratio (TTM) | — | 27.73 |
| Forward P/E | 36.17 | 19.02 |
| EPS (TTM) | $-3.74 | $0.44 |
| Dividend yield | 0.00% | 65.57% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | $638.50M | $3.81B |
| Revenue growth (YoY) | +65.55% | +13.76% |
| Net income (latest FY) | $-183.17M | $663.00M |
| Gross margin | 92.56% | 58.51% |
| Operating margin | -26.12% | 22.09% |
| Net margin | -28.69% | 17.40% |
| 52-week high | $260.19 | $15.67 |
| 52-week low | $119.20 | $11.36 |
| Distance from 52-week high | -34.63% | -22.14% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +67.35% | +8.36% |
| Average volume | 712.30K | 2.87M |
| Shares outstanding | 52.38M | 832.99M |
| Employees | 1,346 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AXSM has outperformed RDY by 56.1 percentage points over the past year.
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (65.57% vs 0.00%).
- Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
- Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs +13.76%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
AXSM vs RDY FAQ
Which is bigger, Axsome Therapeutics or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories (RDY) is larger, with a market capitalization of $10.16B compared with $8.91B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, AXSM or RDY?
AXSM returned +43.27% over the past 12 months, compared with -12.79% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Axsome Therapeutics or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 65.57%, while Axsome Therapeutics does not currently pay a regular dividend.
Are Axsome Therapeutics and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.